MoonLake Immunotherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for MoonLake Immunotherapeutics (MLTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-121.24-44.08-49.97-64.37
Depreciation & Amortization1.380.400.160.01
Stock Based Compensation7.287.119.6510.86
Change in Working Capital-3.78-5.93-1.585.38
Change in Accounts Receivable-1.79-0.84-0.07-0.18
Change in Accounts Payable7.151.58-1.311.88
Change in Other Working Capital-0.23-6.96-0.203.68
Other Operating Activities-0.236.95-14.160.09
Net Cash from Operating Activities-116.59-42.78-55.89-42.21
Investing Activities
Capital Expenditures-0.520.28-0.02-0.06
Purchases of Investments-350.28-24.90-32.320.00
Sales/Maturities of Investments145.20-24.909.900.00
Net Cash from Investing Activities-205.60-25.18-32.34-0.06
Financing Activities
Debt Repayment0.000.00-15.000.00
Common Stock Issued52.54482.450.050.13
Common Stock Repurchased0.000.000.00-0.01
Other Financing Activities-1.47-2.75134.650.00
Net Cash from Financing Activities51.31479.70119.6951.92
Summary
Effect of Forex Changes on Cash0.13-0.080.010.00
Net Change in Cash-270.87411.6631.479.65
Cash at Beginning of Period451.1739.518.040.00
Cash at End of Period180.43-67.9339.510.00
Free Cash Flow-117.11-43.06-55.91-42.27
Supplemental Disclosures
Income Taxes Paid0.150.040.000.00